---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-045170"
form_type: "8-K"
ticker: "IONS"
cik: "0000874015"
company_name: "IONIS PHARMACEUTICALS INC"
filed_at: "2023-09-26T23:59:59+00:00"
generated_at: "2026-06-10T09:03:30.070399+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Ionis reports positive Phase 3 olezarsen results; 100% reduction in pancreatitis in FCS

## Summary
- Olezarsen 80 mg achieved primary endpoint with significant triglyceride reduction vs placebo (p=0.0009) at six months.
- Acute pancreatitis events reduced 100% (0 events for olezarsen vs 11 for placebo) over 12 months.
- Favorable safety profile; no hepatic/renal toxicity, no clinically meaningful platelet reductions.
- Ionis plans to file NDA with FDA early 2024; potential first approved treatment for FCS in US.
- Phase 3 studies continuing in broader severe hypertriglyceridemia (SHTG) population.

## SEC filing metadata
- accession: 0001140361-23-045170
- form_type: 8-K
- ticker: IONS
- cik: 0000874015
- company_name: IONIS PHARMACEUTICALS INC
- filed_at: 2023-09-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874015/000114036123045170/0001140361-23-045170-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874015/000114036123045170/ef20011263_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-045170
- JSON: https://secwatch.observer/filing/0001140361-23-045170.json
- Plain text: https://secwatch.observer/filing/0001140361-23-045170.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.